← Oncology Approval Tracker

FDA DECISION ·

Breyanzi

lisocabtagene maraleucel · Juno Therapeutics (Bristol Myers Squibb)

FDA approvalNew or expanded indicationMantle cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory mantle cell lymphoma after at least two systemic treatment lines, including a BTK inhibitor.

LAMPGEN ANALYSIS

Why it matters

This CAR T indication provides another cellular option after exposure to a BTK inhibitor.

What research teams should watch

Track referral timing, treatment history, bridging therapy and whether patients reached infusion after leukapheresis.

PRIMARY RECORDS

Sources